Allogeneic donor bone marrow cells recovery and infusion after allogeneic face transplantation from the same donor.

摘要

Immunological obstacles to composite tissue allotransplant-ation can be overcome with immunosuppressive drugs.1 However, regarding the risk of chronic rejection the long-term outcome of tissue composite transplant is not known. The decision to include BM cell infusions in the first human facial allotransplantation was based on studies where immunosuppression combined with the infusion of donor BM cells after graft organs led to a decrease in chronic rejection and an improvement of long-term graft survival.2 However, the number of BM cells and preparative conditioning regimen required to induce tolerance of transplant organ have not been determined yet. We are reporting the results of BM infusion associated with a facial transplantation and discussing the characteristics of these cells and their potential role.